First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for treatment of anemia of chronic disease. This phase I First-in-Human study shall investigate safety and pharmacokinetics in healthy human volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

NCT03309241

Healthy Subjects

COMPLETED PHASE1

First in Human Study for PF-06667272

NCT03126149

Healthy

COMPLETED PHASE1

Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

NCT00517855

Healthy Volunteers

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants

NCT04124653

Healthy Participants

COMPLETED PHASE1

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

NCT02509117

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

First-in-Human (FIH), randomized, dose-escalation, double-blind, placebo-controlled single dose in healthy volunteers.

The single rising dose study will enroll 8 subjects per cohort (6 verum, 2 placebo), up to a maximum tolerated dose, defined by stopping rules. 6 dose levels are anticipated. Study drug will be administered as i.v. infusion on Day 1. The decision to escalate the dose by the dose escalation committee (DEC) will be based on an interim analysis of clinical safety and safety laboratory data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRS-080#022-DP

hepcidin antagonist, single administration, ascending doses

Group Type EXPERIMENTAL

PRS-080#022-DP

Intervention Type DRUG

hepcidin antagonist

PRS-080-Placebo#001

Comparotor treatment, single administration

Group Type PLACEBO_COMPARATOR

PRS-080-Placebo#001

Intervention Type DRUG

Placebo treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRS-080#022-DP

hepcidin antagonist

Intervention Type DRUG

PRS-080-Placebo#001

Placebo treatment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PRS-080 Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy Caucasian males: based on a screening examination including medical history, physical examination, 12-lead ECG, vital signs and clinical laboratory profiles, age 18-50 years
2. Subjects should have a body mass index of 18-30 kg/m2 and should weigh 60-90 kg
3. Subjects must be using two acceptable methods for contraception (e.g. spermicide and condom) during the study and refrain from fathering a child in the 3 months following the last dosing.
4. Willing to comply with the requirements of the study protocol and signing the informed consent sheet.

Exclusion Criteria

1. Any uncontrolled or active major systemic disease
2. History or presence of malignancy
3. Definite or suspected history of drug allergy
4. Active acute or chronic infection, including, but not limited to: upper airway infection, urinary tract infection, and skin infection
5. Use of any investigational drug within 30 days, or 5 half-lives, whichever is longer, prior to the planned first drug administration.
6. Use of prescription medication within 14 days prior to the planned first drug administration and throughout the study (with the exception of medications given to treat an adverse event and use of non-prescription or over-the-counter medications within 7 days prior to the planned first drug administration and throughout the study (including vitamins, herbal supplements, or remedies
7. Smoking greater than 20 cigarettes per week
8. History of alcohol or substance abuse within the past 6 months prior to the planned first drug administration
9. History of increased bleeding risk
10. Clinically relevant abnormalities found in physical examination, vital signs measurements, laboratory safety tests or ECG
11. Blood donation within the last 60 days prior to the planned first drug administration
12. Positive results on hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV1/2) antibodies screening
13. Iron overload or disturbance in utilization of iron (defined as ferritin \> 300.0 ng/mL and \< 10.0 ng/mL)
14. i.v. iron treatment or blood transfusion within last 90 days prior to the planned first drug administration or during trial
15. ESA (e.g. Erythropoietin) treatment within the last year
16. Surgery or trauma with significant blood loss within 2 months before the planned first drug administration
17. Not able to abstain from consumption of food or beverages known to influence dietary iron absorption

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes